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Abstract
Surgical therapies in aortic valve stenosis (AVS) and hypertrophic obstructive cardiomyopathy (HOCM) aim to relief intra-
ventricular pressure overload and improve clinical outcome. It is currently unknown to what extent myocardial adaptation 
concurs with restoration of intraventricular pressures, and whether this is similar in both patient groups. The aim of this 
study was to investigate changes in myocardial adaptation after surgical therapies for AVS and HOCM. Ten AVS and ten 
HOCM patients were enrolled and underwent cardiac magnetic resonance cine imaging and myocardial tagging prior to, 
and 4 months after aortic valve replacement (AVR) and septal myectomy, respectively. Global left ventricular (LV) analyses 
were derived from cine images. Circumferential strain was assessed from myocardial tagging images at the septal and lateral 
wall of the mid ventricle. Pressure gradients significantly decreased in both AVS and HOCM after surgery (p < 0.01), with 
a concomitant decrease in left atrial volume (p < 0.05) suggesting lower diastolic filling pressures. Also, LV volumes, mass 
and septal wall thickness decreased in both, but to a larger extent in AVS than in HOCM patients. AVR improved wall thick-
ening (p < 0.05) and did not change systolic strain rate. Myectomy did not affect wall thickening and reduced septal systolic 
strain rate (p = 0.03). Both AVR and myectomy induced positive structural remodeling in line with a reduction of pressure 
overload. A concomitant recovery in systolic function however was found in AVR only. The systolic functional deterioration 
in HOCM patients seems to be inherent to myectomy and the ongoing and irreversible disease.
Keywords Aortic valve stenosis · Hypertrophic obstructive cardiomyopathy · Magnetic resonance imaging · Cardiac 
remodeling
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LV  Left ventricular
LVH  Left ventricular hypertrophy
LVOT  Left ventricular outflow tract
CMR  Cardiovascular magnetic resonance
EDWT  End-diastolic wall thickness
bSSFP  Balanced steady-state free precession
Introduction
Left ventricular hypertrophy (LVH) is a common finding 
in clinical practice and is associated with morbidity and 
mortality. LVH can be detected in acquired and genetic 
cardiac diseases. The most common cause for acquired 
LVH is in aortic valve stenosis (AVS). In response to sys-
tolic pressure overload, the myocardium hypertrophies in 
an attempt to normalize increased wall stress [1]. Patients 
with severe AVS accompanied with LVH have an increased 
risk to develop heart failure in the future [2]. Aortic valve 
replacement (AVR) therapy is recommended in all symp-
tomatic AVS patients, and has been shown to improve left 
ventricular ejection fraction (LVEF), exercise capacity, 
and mortality [3]. Considering genetic cardiomyopathies, 
hypertrophic obstructive cardiomyopathy (HOCM) is the 
most common cause for LVH with a prevalence ranging 
from 1:200 to 1:500 [4]. Sarcomeric mutations affect func-
tional properties of the sarcomeres [5] and impair energy 
metabolism, leading to LVH, most often asymmetric [6, 
7]. This asymmetric hypertrophy in combination with sys-
tolic anterior motion of the mitral valve can cause left 
ventricular outflow tract (LVOT) obstruction, leading to 
heterogeneous symptoms, varying from angina and syn-
cope, to congestive heart failure and sudden cardiac death 
[8]. The surgical treatment for LVOT obstruction is septal 
myectomy, which reduces the risk for sudden cardiac death 
and normalizes left ventricular (LV) pressures [9]. Previ-
ous studies have investigated the effect of AVR and septal 
myectomy on the myocardium separately demonstrating 
a reduction in intraventricular pressures with subsequent 
improvement in clinical symptoms and outcome [10–13]. 
However, it is currently unclear to what extent myocar-
dial structural and functional recovery concurs with res-
toration of intraventricular pressures, and whether this 
is comparable in patient groups with similar concentric 
hypertrophic remodeling, but a different cause (i.e. aortic 
stenosis vs. genetic). In the current study, we use cardiac 
magnetic resonance (CMR) imaging to accurately assess 
structural changes and myocardial function after surgery 
for AVS and HOCM, and compare this change to a group 
of healthy controls. We hypothesize that surgical therapies 
will improve myocardial function in both AVS and HOCM 
patients.
Methods
The study protocol was in agreement with the principles 
outlined in the Declaration of Helsinki and was approved 
by the Medical Ethics Review committees of the partici-
pating hospitals (VU University Medical Center and Onze 
Lieve Vrouwe Gasthuis in Amsterdam, The Netherlands). 
All participants gave written informed consent prior to 
inclusion.
Ten AVS patients eligible for AVR therapy and ten 
HOCM patients eligible for septal myectomy, were pro-
spectively enrolled in the study between October 2011 
and November 2015, as described previously [14]. Inclu-
sion criteria for AVS participants were the presence of 
isolated AVS with a peak transvalvular pressure gradient 
of > 50 mmHg, and an aortic valve area < 1 cm2, according 
to the American Society of Echocardiographic guidelines 
[15]. Inclusion criteria for HOCM participants were LVOT 
peak pressure gradient > 30 mmHg at rest or during provo-
cation, and presence of clinical symptoms, despite optimal 
medical treatment. According to the guidelines to undergo 
surgical intervention in AVS and HOCM patients, differ-
ent cutoff gradients are advised [16, 17]. The exclusion 
criteria were any absolute or relative contra-indication for 
undergoing CMR, the presence of any significant coro-
nary artery disease (> 30%) and a history of hypertension 
in HOCM patients. LVOT gradient and peak aortic valve 
pressure gradient were obtained by Doppler echocardiog-
raphy. Maximal exercise capacity was derived from a cyclo 
ergometry test when patients reached a point of exhaustion 
or symptom limitation, prior to, and after surgical therapy 
with a ramp protocol of 10–20 W min−1. To compare myo-
cardial function in AVS and HOCM patients before sur-
gical therapy, 14 gender-matched healthy subjects were 
included as a control group.
All AVS and HOCM participants underwent a CMR 
scan, 2 weeks prior to, and 4 months after surgery. CMR 
was performed on a 1.5 Tesla whole body scanner (Mag-
netom Sonata or Avanto, Siemens, Erlangen, Germany), 
using a six-channel phased-array body coil. In all patients 
and controls, cine images were obtained using a breath-
hold segmented k-space balanced steady-state free pre-
cession (bSSFP) employing retrospective electrocardio-
graphic gating, with contiguous short axis slices to cover 
the whole ventricle from base to apex. Ventricular volumes 
at end-diastole and end-systole, and mass were obtained 
from the cine short axis images. Left atrial (LA) vol-
umes and emptying fraction (LAEF) were obtained from 
a stack of transversely oriented slices on a two-chamber 
view at the level of the lower leading edge of the mitral 
valve annulus to cover the left atrium [18]. A multiple 
breath-hold, retrospectively triggered bSSFP myocardial 
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sinusoidal complementary tagged (CSPAMM) images 
were acquired to create non-invasive markers (tags) within 
the myocardium [19]. A midventricular short axis plane 
was positioned at 50% of the distance between the mitral 
valve annulus and the endocardial border of the apex. 
Additional details about the CMR acquisition are provided 
in the Data Supplement.
The cine images were analyzed off-line by a single inves-
tigator, using MASS analysis software (Medis medical imag-
ing systems, v2.1, Leiden, The Netherlands). Endocardial 
contours were drawn at end-diastole and end-systole to cal-
culate LV end-diastolic volume (LVEDV), LV end-systolic 
volume (LVESV), and LVEF. Addition of epicardial con-
tours was used to calculate LV mass and wall thickening. 
Tissue tagging images were analyzed by Intag [20] software 
(CREATIS, Lyon, France) to quantify myocardial motion 
using the SinMod technique and estimate regional peak cir-
cumferential strain components (Lagrangian and systolic and 
diastolic strain rate, Fig. 1). Myocardial strain was measured 
in the mid myocardial layer which has been reported to be 
the most reproducible [21]. The software runs as a plug-in 
for OsiriX (v6.5, Pixmeo, Switzerland) [22]. Analysis of the 
LV was calculated according to the 17 segment AHA model 
[23]. To investigate regional effects after surgical treatment 
in both patient groups, strain analyses were derived from the 
septum (average of segment 8 and 9) and lateral wall (aver-
age of segment 11 and 12). Both areas were compared with 
each other. The lateral wall served as a remote area in which 
no regional treatment was performed. Because of the lack 
of tissue tagging on the long axis, global and regional lon-
gitudinal strain was analyzed off-line using CVi 42 software 
(Circle Cardiovascular Imaging, Calgery, Canada). Semi-
automatic endo- and epicardial contours were drawn on the 
four, three and two chamber cine images. To compare septal 
and lateral longitudinal strain, the mean of the four septal 
segments of basal antero- and inferoseptal segments and four 
lateral segments of basal and mid antero- and inferolateral 
segments were calculated.
Statistical analysis was performed using SPSS software 
(version 22.0; SPSS, Chicago, IL, USA). All variables 
were visually checked for normal distribution by appre-
ciation of the histogram with separate needs of the patient 
groups. All data were not normally distributed and pre-
sented by median with interquartile range and was com-
pared to healthy controls with a Mann-Whitney-U test. 
Measurements prior to, and after surgical therapy were 
compared within groups using Wilcoxon signed-rank test. 
Exact Chi square test was used for categorical variables. 
Fig. 1  Representative tagging images of a patient with AVS and 
HOCM with corresponding strain signals. a At end-diastole and end-
systole representative images are shown for a patient with AVS (left) 
and HOCM (right) before (pre) and after (post) surgical treatment. b 
Corresponding peak circumferential strain and systolic circumferen-
tial strain rate curves are presented
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As three separate statistical tests were performed for each 
outcome measure in each group of patients (comparison 
of pre- and post-measurement and separate comparison 
of pre- and post- measurements to the control group) we 
used a two-sided significance level of 0.05/3 to account 
for multiple testing.
Results
Myocardial function in aortic valve stenosis 
before surgery
In the AVS group none of the patients used betablock-
ers, one patient used an ACE inhibitor and four patients 
used a statin before surgery. Pressure gradients were sig-
nificantly higher in AVS with a concomitant higher LA 
volume, as presented in Tables 1 and 2. End-diastolic 
wall thickness (EDWT) was significantly higher com-
pared with controls both in the septum and the lateral wall 
(p < 0.001). Except for LV mass, all global LV dimen-
sions were comparable to controls (Table 2). Septal and 
lateral wall thickening were significantly lower compared 
with controls (Table 3, p < 0.001), whereas only septal 
circumferential strain was significantly reduced (Table 3, 
p = 0.013). Septal systolic strain rate was reduced com-
pared with controls (− 34 [− 44, − 27] vs. − 47 [− 58, 
− 34] %  s−1, p = 0.005). Lateral systolic and diastolic 
strain rates before AVR were similar to controls (Table 3). 
Global longitudinal strain was similar to healthy subjects 
(Fig. 2).
Myocardial function in hypertrophic obstructive 
cardiomyopathy before surgery
In the HOCM group, eight patients used betablockers, one 
used an ACE inhibitor and one used a diuretic before myec-
tomy. At baseline HOCM presented with a lower heart rate, 
probably due to the usage of betablockers (p = 0.003). Pres-
sure gradients were significantly higher in HOCM with a 
concomitant higher LA volume, as listed in Tables 1 and 
4. Regarding global myocardial function, HOCM patients 
had smaller LVESV, higher LVEF, and higher LV mass 
compared to controls (Table 4). Septal and lateral EDWT 
were higher than controls (Table 5, p < 0.001). Septal wall 
thickening and septal circumferential strain were signifi-
cantly reduced compared with controls (Table 5, p < 0.01). 
Similar to AVS patients, septal systolic and diastolic strain 
rate were reduced compared with controls before myectomy 
(− 28 [− 44, − 17] vs. − 47 [− 58, − 34] %  s−1, p = 0.005; 13 
[9, 33] vs. 36 [26, 39] %  s−1, p = 0.02, resp.). Lateral sys-
tolic and diastolic strain rate were comparable to controls 
(Table 5). Interestingly, there were no differences between 
systolic and diastolic strain rates between AVS and HOCM 
patients before surgery (for both p = 0.53). Global longitudi-
nal strain was significantly affected compared with controls 
(− 16 [− 19, − 14] vs. − 22 [23, − 19] %, p = 0.007, Fig. 2).
Effect on myocardial function after aortic valve 
replacement
Both peak and mean transvalvular pressure gradients in 
AVS patients significantly decreased after surgery (from 
85 [72, 107] to 23 [14, 32] mmHg, and from 49 [42, 62] 
Table 1  Baseline characteristics of controls, aortic valve stenosis and hypertrophic cardiomyopathy patients
Data is presented as median and interquartile range
Ao aortic, AVS aortic valve stenosis, DBP diastolic blood pressure, HOCM hypertrophic obstructive cardiomyopathy, LVOT left ventricular out-
flow tract, MAP mean arterial pressure, NA not applicable, POST after surgical therapy, PRE before surgical therapy, SBP systolic blood pressure
*Measured by Doppler echocardiography
Controls (n = 14) HOCM pre-
myectomy 
(n = 10)
AVS pre-AVR 
(n = 10)
p-value HOCM 
pre-myectomy 
versus controls
p-value AVS 
pre-AVR versus 
controls
p-value HOCM 
pre-myectomy versus 
AVS pre-AVR
Age (years) 50 [40, 57] 53 [47, 65] 59 [54, 68] 0.37 0.009 0.14
Gender (male/
female)
9/5 6/4 7/3 0.83 0.77 0.64
SBP (mmHg) 119 [112, 134] 106 [103, 123] 123 [107, 130] 0.04 0.55 0.06
DBP (mmHg) 71 [65, 75] 59 [57, 70] 72 [60, 78] 0.03 0.89 0.22
MAP (mmHg) 88 [81, 94] 76 [71, 88] 89 [76, 95] 0.03 0.71 0.14
Peak gradient Ao/
LVOT (mmHg)*
NA 26 [15, 54] 85 [72, 107] NA NA 0.001
Mean gradient Ao/
LVOT (mmHg)*
NA 14 [8, 23] 49 [42, 62] NA NA < 0.001
Heart rate (/min) 69 [63, 78] 59 [57, 61] 68 [63, 70] 0.003 0.403 0.005
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to 11 [7, 15] mmHg, p = 0.005, respectively). Global LV 
dimensions and LA volume decreased after AVR, how-
ever there was no significant change in LVEF and LAEF 
(Table 2). Lateral wall thickening significantly improved 
after AVR and septal wall thickening showed a trend 
towards improvement albeit non-significant compared to 
before AVR (Table 3; Fig. 1 Supplemental Material). Both 
global (− 14 [− 16, 13] to − 17 [− 18, − 14] %, p = 0.4) 
and regional circumferential strain did not significantly 
improve after surgery (Table 3). Global longitudinal strain 
improved after AVR therapy (− 20 [− 23, − 20] to − 22 
[− 23, − 20] %, p = 0.013, Fig. 2), with no differences 
between septal and lateral segments (Table 1 Supplemen-
tary Material). The amount of LGE after surgery did not 
change. Nonetheless, exercise capacity during cardiopul-
monary exercise test showed a significant improvement 
from 155 [89, 216] to 161 [97, 224] Watt, p = 0.008. Peak 
VO2 only showed a trend toward improvement (1.98 [1.36, 
2.61] vs. 2.21 [1.52, 2.74] L min−1, p = 0.06).
Effect on myocardial function after septal myectomy
From a total of ten HOCM patients, one patient declined 
follow up CMR, and another patient underwent pacemaker 
implantation due to an atrioventricular block. Measurements 
at baseline were included from ten patients, and at follow-
up from the remaining eight patients. Both LVOT peak 
and mean gradients improved after septal myectomy (from 
26 [15, 54] to 5 [3, 9] mmHg and 14 [8, 23] to 8 [5, 19] 
mmHg, p = 0.02, respectively). As was to be expected, sep-
tal EDWT decreased following myectomy. Also, LV mass 
and LA dimension decreased after myectomy, but without 
a change in LV dimensions, LVEF or LAEF (Table 4). 
Although wall thickening showed a non-significant dif-
ference after myectomy (Fig. 1 Supplementary Material), 
global circumferential strain did not improve after myec-
tomy (− 13 [− 16, − 11] to − 14 [− 15, − 11] %, p = 0.52). 
With respect to regional circumferential strain only septal 
circumferential strain further deteriorated with worsening of 
septal systolic strain rate (Table 5). Additionally global and 
Table 2  Aortic valve stenosis before (PRE) and after (POST) aortic valve replacement: global characteristics
Data is presented as median (interquartile range)
CO cardiac output, EDV end-diastolic volume, ESV end-systolic volume, AVR aortic valve replacement, AVS aortic valve stenosis, LGE late gad-
olinium enhancement, LVM LV mass, LAEF left atrial emptying fraction, LVEF LV ejection fraction, POST after surgical therapy, PRE before 
surgical therapy, SV stroke volume, VO2 oxygen consumption
*Measured by Doppler echocardiography
Controls (n = 14) AVS pre-AVR 
(n = 10)
p-value controls 
versus AVS pre-
AVR
AVS post-AVR 
(n = 10)
p-value AVS pre-
AVR versus AVS 
post-AVR
p-value AVS 
post-AVR versus 
controls
Global LV characteristics
 LV EDV (ml m−2) 90 [81, 104] 101 [84, 118] 0.29 84 [74, 102] 0.01 0.59
 LV ESV (ml m−2) 36 [26, 40] 40 [29, 55] 0.29 31 [26, 39] 0.01 0.55
 LVEF (%) 61 [57, 66] 59 [52, 64] 0.37 63 [59, 66] 0.29 0.67
 SV (ml) 114 [101, 124] 111 [97, 128] 0.89 106 [86, 127] 0.17 0.63
 CO (L min−1) 7.9 [6.5, 8.8] 8.0 [7, 10.1] 0.47 7.1 [6.2, 8.2] 0.01 0.29
 LVM (g m−2) 50 [44, 54] 94 [79, 119] < 0.001 72 [59, 89] 0.005 < 0.001
 LGE mass (%) LV 0 0 [0, 1.4] NA 0 [0, 1.4] 0.99 NA
LA characteristics
 LA volume 
(ml m−2)
45 [42, 50] 60 [53, 66] < 0.001 48 [40, 57] 0.005 0.55
 LAEF (%) 57 [54, 29] 53 [47, 58] 0.15 55 [48, 59] 0.24 0.37
Pressure gradients
 Peak gradient Ao 
(mmHg)*
NA 85 [72, 107] NA 23 [14, 32] 0.005 NA
 Mean gradient Ao 
(mmHg)*
NA 49 [42, 62] NA 11 [7, 15] 0.005 NA
Cardiopulmonary exercise test
 Peak VO2 
(L min−1)
NA 1.98 [1.36, 2.61] NA 2.21 [1.52, 2.74] 0.06 NA
 Exercise capacity 
(Watt)
NA 155 [89, 216] NA 161 [97, 224] 0.008 NA
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regional longitudinal strain did not improve after myectomy 
(Fig. 3; Table 1 Supplementary Material). The amount of 
late gadolinium enhancement showed no significant increase 
after myectomy. Similar to AVS, septal myectomy showed a 
significant increase in exercise capacity during cardiopulmo-
nary exercise test (140 [105, 170] vs. 152 [121, 221] Watt, 
p = 0.043), while peak VO2 remained similar (1.89 [1.26, 
2.05] vs. 1.92 [1.50, 2.79] L min−1, p = 0.89).
Difference in myocardial adaptation after aortic 
valve replacement and septal myectomy
In both patient groups, there was a significant reduction 
in intraventricular pressure gradients with a concomitant 
decrease in LA volume (p < 0.01), suggesting lowering of 
diastolic filling pressures. Wall thickening improved after 
AVR, albeit without improvement in strain and strain rates. 
Similar to AVS patients, strain rates of the lateral wall 
were not affected after surgery for HOCM, while septal 
systolic circumferential strain rate further deteriorated, 
probably as a consequence of the myectomy. Both AVS 
and HOCM patients showed a reduction in LV wall thick-
ness and mass after surgery, though this effect was more 
pronounced in AVS patients (p < 0.05, Fig. 3). Interest-
ingly, both patient groups had an improvement in exercise 
capacity, most likely associated to the relieve in outflow 
obstruction.
Table 3  Aortic valve stenosis before (PRE) and after (POST) aortic valve replacement: regional characteristics
Data is presented as median (interquartile range)
AVR aortic valve replacement, AVS aortic valve stenosis, ED end-diastolic, POST after surgical therapy, PRE before surgical therapy
a Due to tagfading two patients were excluded from lateral diastolic strain rate analysis
Controls (n = 14) AVS pre-AVR 
(n = 10)
p-value controls 
versus AVS pre-
AVR
AVS post-AVR 
(n = 10)
p-value AVS 
pre-AVR versus 
AVS post-AVR
p-value AVS 
post-AVR versus 
controls
Septal wall ED wall thick-
ness (mm)
6 [6, 7] 11 [11, 13] < 0.001 9 [8, 10] 0.005 < 0.001
Wall thickening 
(%)
80 [64, 97] 37 [33, 59] 0.001 54 [43, 74] 0.10 0.013
Circumferential strain
 Peak circum-
ferential 
strain (%)
− 17 [− 18, − 14] − 14 [− 16,− 12] 0.013 − 16 [− 18, 
− 13]
0.11 0.37
 Peak systolic 
circumferen-
tial strain rate 
(%  s−1)
− 47 [− 58, − 43] − 34 [− 44, − 27] 0.005 − 40 [− 53, 
− 32]
0.20 0.14
 Peak diastolic 
circumferen-
tial strain rate 
(%  s−1)
36 [26, 39] 27 [12, 43] 0.29 26 [22, 42] 0.24a 0.57
Lateral wall  ED wall thick-
ness (mm)
6 [5, 6] 10 [9, 11] < 0.001 9 [8, 9] 0.01 < 0.001
 Wall thickening 
(%)
91 [77, 110] 31 [27, 52] < 0.001 54 [38, 77] 0.01 0.01
Circumferential strain
 Peak circum-
ferential 
strain (%)
− 17 [− 19,− 13] − 16 [− 21,− 10] 0.84 − 16 [− 21,− 12] 0.88 0.98
 Peak systolic 
circumferen-
tial strain rate 
(%  s−1)
− 37 [− 50,− 26] − 50 [− 72, −30] 0.24 − 45 [− 51,− 38] 0.46 0.19
 Peak diastolic 
circumferen-
tial strain rate 
(%  s−1)
13 [10, 18] 17 [13, 26] 0.13 18 [12, 25] 0.35a 0.19
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Discussion
This study provided the unique opportunity to prospectively 
investigate myocardial function in patients with two different 
etiologies in LVH, and to what extent reverse remodeling 
occurs in AVS and HOCM patients after surgical treatment, 
AVR and septal myectomy respectively. The main find-
ings of the present study are that (1) both AVS and HOCM 
patients have significantly higher LV mass and LA volumes 
than controls, and in HOCM smaller LV volumes compared 
with AVS patients and controls; (2) both patient groups had 
lower septal wall thickening and systolic strain rates than 
controls; (3) both patient groups demonstrated reversed 
structural remodeling after surgery, with improved intra-
ventricular pressure gradients and a concomitant decrease in 
LA volume, decreased wall thickness and LV mass; (4) only 
AVS patients showed functional improvement after surgical 
treatment, evident from improved global wall thickening but 
unaffected strain rates, whereas HOCM patients deteriorated 
with respect to septal wall thickening and systolic strain rate.
In both patient groups, intraventricular pressure gradi-
ents improved after surgery with a concomitant reduced LA 
volume, probably reflecting improved diastolic pressures. 
Fig. 2  Global longitudinal strain. Global longitudinal strain is 
depicted for AVS before (pre) and after (post) surgery, HOCM before 
(pre) and after (post) surgery and healthy controls. AVS patients 
showed similar longitudinal strain compared with healthy controls 
both before and after AVR therapy. HOCM patients revealed a signif-
icantly lower longitudinal strain compared with healthy controls even 
after myecomy. †p < 0.01 versus controls. *p < 0.05 follow up versus 
baseline. All data is presented by median with interquartile range. 
AVS  aortic valve stenosis; HOCM   hypertrophic obstructive cardio-
myopathy
Table 4  Hypertrophic obstructive cardiomyopathy before (PRE) versus after (POST) septal myectomy: global characteristics
Data is presented as median (interquartile range)
HOCM hypertrophic obstructive cardiomyopathy; other abbreviations as in Table 2
Controls (n = 14) HOCM pre-
myectomy 
(n = 10)
p-value controls vs 
HOCM pre-myec-
tomy
HOCM post-
myectomy 
(n = 8)
p-value HOCM 
pre-myectomy 
versus HOCM post-
myectomy
p-value HOCM post-
myectomy versus 
controls
Global LV characteristics
 LV EDV (ml  m−2) 90 [81, 104] 93 [78, 104] 0.93 76 [67, 96] 0.16 0.21
 LV ESV (ml  m−2) 36 [26, 40] 24 [21, 31] 0.02 25 [20, 29] 0.67 0.24
 LVEF (%) 61 [57, 66] 73 [65, 74] 0.009 66 [61, 73] 0.21 0.13
 SV (ml) 114 [101, 124] 133 [92, 166] 0.34 112 [91, 146] 0.21 0.92
 CO (L  min−1) 7.9 [6.5, 8.8] 7.6 [2.8, 10] 0.55 8.4 [7.3, 9.5] 0.26 0.53
 LVM (g  m−2) 50 [44, 54] 92 [90, 114] < 0.001 81 [67, 91] 0.03 < 0.001
 LGE mass (%) LV 0 4.0 [1.7, 11.3] NA 4.9 [1.1, 36.4] 0.88 NA
LA characteristics
 LA volume (ml 
 m−2)
45 [42, 50] 84 [69, 114] < 0.001 62 [51, 80] 0.012 < 0.001
 LAEF (%) 57 [54, 29] 41 [27, 46] < 0.001 46 [42, 54] 0.16 0.002
Pressure gradients
 Peak gradient 
LVOT (mmHg)*
NA 14 [8, 23] NA 8 [5, 19] 0.02 NA
 Mean gradient 
LVOT (mmHg)*
NA 26 [15, 54] NA 5 [3, 9] 0.02 NA
Cardiopulmonary exercise test
 Peak VO2 (L 
 min−1)
NA 1.89 [1.26, 2.05] NA 1.92 [1.50, 2.79] 0.89 NA
 Exercise capacity 
(Watt)
NA 140 [105, 170] NA 152 [121, 221] 0.043 NA
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AVR is known to improve symptoms, reduce LV mass and 
wall thickness [24, 25], which is in line with the results in 
our cohort. Whereas Staron and colleagues demonstrated 
improvement in echocardiographic circumferential strain 
after AVR [26], in our cohort we found an even greater 
improvement comparable to normal values, suggesting that 
AVR reversibly affects the LV. A previous study using myo-
cardial tagging showed global diastolic dysfunction before 
AVR and improvement after surgery [27]. This may be 
explained by the delayed and prolonged diastolic untwist-
ing in AVS before AVR [28]. In this study AVS patients had 
normal diastolic function before AVR similar to controls, 
probably due to an earlier timing of the surgical intervention. 
While there is still debate to advise betablockers in order to 
reduce afterload in AVS patients [3], in our cohort none of 
the patients used betablockers. Taken together these findings 
confirm the benefit of decreasing the pressure gradient by 
valve replacement, thereby restoring structure and function 
and ultimately improving exercise capacity.
Whereas the increased pressure gradient in AVS is a 
static phenomenon, the pressure gradient in HOCM is of 
a dynamic nature, mainly depending on loading conditions 
[16]. Septal myectomy and alcohol ablation are both equally 
effective at reducing LVOT obstruction, however, septal 
myectomy is shown to be more effective in improving exer-
cise parameters and results in a consistent septum reduction 
[29]. This study demonstrated a reduction in LV mass and 
septal wall thickness which is in line with previous results 
[30]. Although myectomy demonstrated reversed struc-
tural remodeling at the septum, surgery may have induced 
Table 5  Hypertrophic obstructive cardiomyopathy before (PRE) versus after (POST) septal myectomy: regional characteristics
Data is presented as median (interquartile range)
HOCM  hypertrophic cardiomyopathy; other abbreviations as in Table 4
a Due to tagfading two patients were excluded from diastolic strain rate analysis
Controls (n = 14) HOCM pre-
myectomy 
(n = 10)
p-value controls 
versus HOCM 
pre-myectomy
HOCM post-
myectomy 
(n = 8)
p-value HOCM 
pre-myectomy 
versus post-
myectomy
p-value HOCM 
post-myectomy 
versus controls
Septal wall ED wall thick-
ness (mm)
6 [6, 7] 15 [13, 17] < 0.001 13 [10, 16] 0.04 < 0.001
Wall thickening 
(%)
80 [64, 97] 50 [33, 66] 0.009 61 [36, 63] 0.33 0.02
Circumferential strain
 Peak circumfer-
ential strain 
(%)
− 17 [− 18, − 14] − 10 [− 15, − 9] 0.003 − 8 [− 10, − 7] 0.02 < 0.001
 Peak systolic 
circumferen-
tial strain rate 
(%  s−1)
− 47 [− 58, − 43] − 28 [− 44, − 17] 0.005 − 13 [− 17, − 6] 0.03 < 0.001
 Peak diastolic 
circumferen-
tial strain rate 
(%  s−1)
36 [26, 39] 13 [9, 33] 0.02 15 [10, 23] 0.46a 0.002
Lateral wall ED wall thick-
ness (mm)
6 [5, 6] 10 [9, 12] < 0.001 10 [8, 11] 0.78 < 0.001
Wall thickening 
(%)
91 [77, 110] 83 [49, 128] 0.71 98 [60, 123] 0.26 0.97
Circumferential strain
 Peak circumfer-
ential strain 
(%)
− 17 [− 19, − 13] − 16 [− 19, − 13] 0.78 − 19 [− 21, − 16] 0.17 0.22
 Peak systolic 
circumferen-
tial strain rate 
(%  s−1)
− 37 [− 50, − 26] − 46 [− 56, − 32] 0.48 − 53 [− 64, − 42] 0.23 0.046
 Peak diastolic 
circumferen-
tial strain rate 
(%  s−1)
13 [10, 18] 15 [11, 22] 0.44 17 [11, 22] 0.92a 0.40
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myocardial dysfunction. Global dysfunction of circumferen-
tial strain was also seen by Moravsky et al. by echocardiog-
raphy [10], which is in agreement with our measurements 
by CMR. Regional analysis demonstrated impaired septal 
systolic and diastolic function before surgery, whereas the 
lateral wall showed similar values compared to healthy con-
trols. The differences between septum and lateral wall may 
be explained by the difference of tissue characteristics. At 
the hypertrophied septum tissue characteristics demonstrate 
increased amount of extracellular volume and myocardial 
disarray compared with the lateral wall. These myocardial 
differences are in accordance with a longitudinal study in 
HOCM patients after alcohol septum ablation, in which sep-
tal systolic function further deteriorated after intervention 
Fig. 3  Change after surgery between AVS and HOCM. Change after 
surgery between AVS (n = 10) and HOCM (n = 8) are depicted for 
LV myocardial mass, left atrial volume, circumferential strain and 
regional systolic and diastolic stain rates. Values above zero in strain 
rates indicate improved strain, values below zero indicate reduced 
strain. An asterisk (*) indicates significant change within AVS or 
HOCM before vs after surgery (p-values are mentioned in Tables 2, 
4). All data is presented by median with interquartile range. After sur-
gery, HOCM demonstrates deterioration of septal systolic strain rate 
compared with AVS. Changes after surgery in regional diastolic strain 
rates were similar in HOCM compared to AVS. AVS  aortic valve 
stenosis, HOCM  hypertrophic obstructive cardiomyopathy, LA  left 
atrial, LV  left ventricular
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[11]. Sommer et al. demonstrated reduced longitudinal strain 
up to 3 years after alcohol septal ablation in HOCM patients 
[31]. The current study also demonstrated reduced longitudi-
nal strain even after myectomy, while contrast enhancement 
was similar compared to before myectomy [32]. In contrast 
to septal alcohol ablation therapy in HOCM patients, where 
a myocardial infarction is induced to achieve septal reduc-
tion which leads to increased scarring [11]. In our HOCM 
population scar is not responsible for the functional deterio-
ration after myectomy. This implies that other mechanisms 
may be responsible for this loss in function, such as loss of 
myocyte integrity or progression of myocyte disarray [33]. 
In addition, the presence of sarcomere mutations continue 
to cause inhomogeneous contraction of the sarcomeres in 
the remaining cardiomyocytes after septal myectomy and 
consequently further reduce myocardial function. Although 
myectomy did not improve regional function in our popula-
tion, a recent study demonstrated that myectomy in HOCM 
patients had a positive effect on the incidence of sudden 
cardiac death and implantable cardioverter-defibrillator 
discharge [34]. However, to be able to better understand 
and define the pathological process of functional loss of the 
myocardium, future studies using new imaging techniques, 
such as extracellular volume fraction assessment using T1 
mapping, may be useful [35].
Diastolic dysfunction is a hallmark of HOCM, and seems 
to be largely caused by increased interstitial fibrosis leading 
to reduced LV compliance [36]. The reduction in LA volume 
after myectomy in our population suggests an improvement 
in diastolic intraventricular pressures, this study however did 
not demonstrate improvement in global or regional diastolic 
function, which might be explained by the reduced LV com-
pliance [37]. Accordingly, an echocardiographic study also 
revealed reduction in LA volume without improvement in 
diastolic function and might be related to the disease history 
and increased development of interstitial fibrosis [12]. Sum-
marizing, our findings we demonstrate reversed structural 
remodeling after myectomy, and worsening of functional 
remodeling at the septum. Even though functional remod-
eling deteriorated after surgery, HOCM patients managed to 
improve exercise capacity, which seems to be a direct result 
of relieving the LVOT obstruction by myectomy [29].
The present study demonstrates reversed structural 
remodeling in both AVS and HOCM patients after surgery, 
however, recovery in systolic function was only seen in 
AVS. Furthermore, HOCM patients demonstrated systolic 
functional deterioration which seems to be inherent to septal 
myectomy and the ongoing and irreversible cardiac patho-
physiology. Although septal myectomy reduces the risk of 
sudden cardiac death, this study emphasizes the need for 
future research in therapies to enhance myocardial recovery.
However, there are several limitation in this study. Several 
medical centers were involved in the inclusion of patients 
for advanced imaging before and after cardiac surgery, and 
therefore, the included patients do not reflect the actual num-
ber of patients who yearly undergo cardiac surgery. As the 
number of participants included were limited, the conclu-
sions should be interpreted carefully. Yet, even with this 
relative small study population we were able to demonstrate 
differences in myocardial adaptation after surgery for AVS 
and HOCM. Although tissue tagging is a novel and accu-
rate method to assess myocardial function, tagline fading in 
end-diastole occurred in two patients who were therefore 
excluded from the diastolic strain rate analysis. Accurate 
detection of diffuse fibrosis using T1 mapping might have 
increased our understanding of the absence of functional 
recovery in HOCM. Furthermore, evaluation by CMR was 
performed at 4 months after surgery which seems reason-
able but not necessarily the optimal timing to capture full 
remodeling and functional recovery.
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